Osimertinib (Tagrisso) broke the $5 billion mark for the first time this year, up 13% year-over-year. Sales in the United States were US$1.780 billion (+14%), mainly due to first-line and adjuvant treatment indications, covering more patient populations, but some of them were reduced by second-line treatment drugs, and difficulties in diagnosis and testing brought about by the epidemic offset.
Market Data 
Markets 
AI
